目的 汇总分析2017—2019年天津医科大学朱宪彝纪念医院门诊患者降脂药物的使用情况及发展趋势，为降脂药的临床合理应用提供科学依据。方法 选取2017—2019年天津医科大学朱宪彝纪念医院门诊降脂类药物的相关数据，采用WHO推荐的限定日剂量（DDD）、用药频度（DDDs）、日均费用（DDC）和排序比（B/A）等对选定的降脂药物进行统计分析。结果 2017—2019年该院降脂药的销售额比较稳定，呈逐年上升趋势。其中他汀类降脂药销售额最高，占比最多，连续3年始终占据首位，其次是贝特类。具体药物中阿托伐他汀（立普妥）连续3年排名第1位；瑞舒伐他汀钙胶囊2017、2018年基本稳定，2019年下降幅度较大；2017—2019年阿托伐他汀的DDDs排名第1位，非诺贝特的DDDs连年上升，且排名第2位；氟伐他汀连续3年最低。DDC值最高的是普罗布考，最低的是苯扎贝特。2017—2019年大部分药品的B/A值都在1.00左右，同步率较好。结论 2017—2019年天津医科大学朱宪彝纪念医院降脂药物的选择与使用相对合理，药品种类逐渐增多，患者用药情况符合指南要求，国家集采政策的实施，2019年患者的药品费用大幅下降。

Objective To summarize and analyze the utilization and development trend of hypolipidemic drugs in outpatients of A tertiary hospital in Tianjin from 2017 to 2019, in order to provide references for clinical rational drug use. Methods The amount, consumption sum, frequency of drug use (DDDs), defined daily cost (DDC), and drug sequence ratio (B/A) of hypolipidemic drugs in A tertiary hospital in Tianjin from 2017 to 2019 were calculated and analyzed statistically. Results From 2017 to 2019, the sales of hypolipidemic drugs were relatively balanced, showing an upward trend year by year. Among them, the sales volume of statins-related drugs is the highest, accounting for the largest proportion, and has always occupied the first place for three consecutive years, followed by the bethe drugs. Among the specific drugs, atorvastatin (Lipitor) ranked the first for three consecutive years. Rosuvastatin calcium capsules were basically stable in 2017 and 2018, and decreased significantly in 2019. From 2017 to 2019, DDDs of atorvastatin ranked first, while fenofibrate increased steadily and ranked second. Fluvastatin was the lowest for three consecutive years. The highest DDC is probucol and the lowest was bezafibrate in 2017—2019. The B/A value of most drugs is about 1.00 and with good synchronicity in 2017—2019. Conclusion The selection and use of antihypertensive drugs for hyperlipidemia patients in A tertiary hospital in Tianjin from 2017 to 2019 are relatively, the types of drugs increased gradually, and the medication situation of patients met the requirements of the guidelines, with the implementation of the national centralized purchase policy, the drug costs of patients will drop significantly in 2019.

R977

天津市科技计划项目（20KPHDRC00020）